dextran dialdehyde

12/01/2008 - "The mice receiving the composition of isoniazid and dialdehyde dextran were characterized by a more significant decrease in the number and size of BCG granulomas, lower severity of destructive changes in the liver parenchyma, and more pronounced reparative regeneration (compared to animals of the isoniazid group)."
12/01/2008 - "Cytomorphological changes in BCG granulomas of the liver and lungs were compared during spontaneous tuberculous inflammation and after intraperitoneal injection of dialdehyde dextran for 5 months. "
12/01/2008 - "Structural changes in the liver parenchyma and granulomas of mice with chronic BCG granulomatosis during therapy with composition of isoniazid and dialdehyde dextran."
12/01/2008 - "The number and size of hepatic granulomas decreased, while the count of degenerated and necrobiotic hepatocytes in infected animals increased 3 months after the start of therapy with a composition of isoniazid and dialdehyde dextran. "
12/01/2008 - "Administration of dialdehyde dextran to mice infected with mycobacteria of BCG vaccine was followed by a decrease in the number and size of BCG granulomas in organs, contributed to the increase in the count of fibroblasts in hepatic and pulmonary granulomas, decreased the severity of destructive changes in the liver parenchyma, promoted reparative processes in hepatocytes, and reduced the degree of fibrosis in the liver and lungs due to a decrease in fibroplastic activity of fibroblasts in BCG granulomas."

12/01/2008 - "Therapeutic efficacy of a composition of amphotericin B and dialdehyde dextran in kidney damage in mice of various strains with systemic candidiasis."
12/01/2008 - "The therapeutic efficacy of a composition of amphotericin B and dialdehyde dextran was much higher than that of amphotericin B in the therapy for systemic candidiasis. "
12/01/2008 - "A composition of amphotericin B and dialdehyde dextran was used for the therapy of male C57Bl/6 mice with systemic candidiasis. "
12/01/2008 - "Granulomatous inflammation in the lungs of mice with systemic candidiasis receiving a composition of amphotericin B and dialdehyde dextran."
04/01/2007 - "Lysosomotropic composition of dialdehyde dextran and amphotericin B had a greater therapeutic effect in mice with systemic candidiasis compared to free amphotericin B. "

12/01/2008 - "Administration of dialdehyde dextran to mice infected with mycobacteria of BCG vaccine was followed by a decrease in the number and size of BCG granulomas in organs, contributed to the increase in the count of fibroblasts in hepatic and pulmonary granulomas, decreased the severity of destructive changes in the liver parenchyma, promoted reparative processes in hepatocytes, and reduced the degree of fibrosis in the liver and lungs due to a decrease in fibroplastic activity of fibroblasts in BCG granulomas."

09/01/1998 - "The biosafety of a new hydrogel wound dressing material consisting of dextran dialdehyde cross-linked gelatin was evaluated (i) in vitro in cultures of dermal fibroblasts, epidermal keratinocytes, and endothelial cells, three cell types which play a major role in the process of cutaneous wound healing, and (ii) in vivo by subcutaneous implantation studies in mice. "
06/02/2023 - "Herein, a novel, self-healing, and antibacterial carboxymethyl chitosan/polyaldehyde dextran (CMCS/PD) hydrogel is designed as the first-aid tissue adhesive for effective trauma emergency management. "

12/01/2008 - "Effect of antifungal preparation amphotericin B and its lysosomotropic composition with dialdehyde-dextran on functional state of phagocytizing cells in the dynamics of granulomatous inflammation induced by C. "
12/01/2008 - "Cytomorphological changes in BCG granulomas of the liver and lungs were compared during spontaneous tuberculous inflammation and after intraperitoneal injection of dialdehyde dextran for 5 months. "
12/01/2008 - "Granulomatous inflammation in the lungs of mice with systemic candidiasis receiving a composition of amphotericin B and dialdehyde dextran."